NVCR — NovoCure Limited

Novocure (NVCR) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Revenues: $167 million, an 8% increase year-over-year, driven primarily by a 5% growth in active GBM patients.
• Gross Margin: 73%, impacted by the global rollout of HFE arrays, ongoing lung cancer launch, and increased tariffs.
• Operating Expenses:
  • R&D: $54 million (up 4% YoY).
  • Sales & Marketing: $59 million (down 2% YoY).
  • G&A: $46 million (up 15% YoY).
• Net Loss: $37 million, with a loss per share of $0.33.
• Adjusted EBITDA: Negative $3 million, ahead of internal plans.
• Cash and Investments: $1.034 billion, with plans to retire $561 million in convertible notes.

2. Strategic Updates and Business Highlights

• GBM Business: Active patients grew to 4,277, with significant contributions from France, Japan, and Germany. The U.S. patient count remained flat.
• Lung Cancer Launch: Currently at 100 active patients, facing challenges in adoption due to competition and physician education.
• Upcoming Launches: Anticipated launches for pancreatic cancer and brain metastases in 2026, leveraging existing infrastructures.
• Regulatory Progress: Positive updates on PANOVA-3 and METIS trials, with submissions to FDA and European regulators underway.
• Product Development: New patient app launched, with 78% adoption among U.S. GBM patients, and improvements in prescription processes for physicians.

3. Forward Guidance and Outlook

• Profitability Goal: Targeting breakeven on an adjusted EBITDA basis by 2027, with expected revenues of $700 million to $750 million.
• Growth Strategy: Focus on expanding Tumor Treating Fields to four cancer indications by year-end 2026, with ongoing investments in infrastructure and product enhancements.

4. Bad News, Challenges, or Points of Concern

• Lung Cancer Launch: The launch has been slower than expected, with a decline in prescription volumes and challenges in physician adoption.
• U.S. Market Dynamics: Difficulty in convincing oncologists to prioritize device-based therapies over clinical trials, particularly in academic centers.
• Inventory Obsolescence: Recognized a $2.9 million expense related to Optune Lua arrays.
• Regulatory Risks: Dependence on successful FDA approvals for new indications and reimbursement processes.

5. Notable Q&A Insights

• Lung Cancer Strategy: Adjustments being made to target physicians with high interest rather than just high patient volumes. Emphasis on education for entire practice teams.
• Reimbursement Updates: Positive trends in commercial reimbursement, but Medicare remains a longer journey. NCCN guidelines are expected to be updated soon.
• Spain Market Dynamics: Anticipated ramp-up in Spain will take time, similar to Japan's past experience, with a gradual increase in patient adoption expected.
• LUNAR-4 Termination: Decision to terminate the trial was based on cost-saving measures and the ability to gather data through real-world evidence.

Overall, Novocure is navigating a complex landscape with solid growth in its GBM business while facing challenges in the lung cancer market. The company remains focused on expanding its reach and achieving profitability through strategic launches and product development initiatives.